MEDIUS HOLDINGS (3154) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Despite higher revenue, this earnings period resulted in lower operating income due to deteriorating profitability in the core Medical Equipment Sales Business. Revenue was ¥227.68B (+3.7% YoY), operating income was ¥1.92B (-5.1%), ordinary income was ¥2.29B (-4.8%), and net income attributable to shareholders of the parent was ¥1.28B (-6.4%). Despite higher revenue, segment income in the Medical Equipment Sales Business declined 9.1%, and the coexistence of revenue growth and profit decline is the defining feature of consolidated performance.

Factors Affecting Earnings

【Revenue】Revenue was ¥227.68B, representing a 3.7% YoY increase. The Medical Equipment Sales Business generated ¥222.92B (+3.7%), while the Nursing Care and Welfare Business generated ¥4.77B (+4.1%), with both segments contributing to revenue growth. The Medical Equipment Sales Business accounted for 97.9% of total revenue, meaning that consolidated performance is largely linked to trends in this business.

【Profit and Loss】Operating income was ¥1.92B (-5.1%), ordinary income was ¥2.29B (-4.8%), and net income was ¥1.28B (-6.4%), with all three declining. The primary factor was a decline in the segment profit margin of the Medical Equipment Sales Business from 3.84% to 3.37%, resulting in segment income for the business declining 9.1% YoY to ¥7.51B. Meanwhile, the profit margin of the Nursing Care and Welfare Business improved from 8.93% to 9.78% (income of ¥0.47B, +14.1%), but its small scale limited its contribution to consolidated results. The divergence between ordinary income and net income was largely attributable to the tax burden; the effective tax rate was high at 46.5%, weighing on final profit. Special income of ¥0.12B, including a ¥0.12B gain on the sale of investment securities, exceeded special losses of ¥0.02B and provided a temporary underpinning for profit before tax. In conclusion, the company achieved revenue growth but recorded lower profit.

Segment Analysis

The Medical Equipment Sales Business recorded revenue of ¥222.92B (+3.7% YoY) and segment income of ¥7.51B (-9.1%), with its segment profit margin declining to 3.37% from 3.84% a year earlier. The business accounted for 94.1% of total consolidated segment income and is the core business driving consolidated performance. The Nursing Care and Welfare Business recorded revenue of ¥4.77B (+4.1%) and segment income of ¥0.47B (+14.1%), with its profit margin improving to 9.78% from 8.93% a year earlier. Adjustments for corporate expenses and other items were negative ¥6.05B, an improvement from negative ¥6.64B in the prior year, but this was insufficient to offset the decline in profit from the Medical Equipment Sales Business. Both segments recorded small impairment losses on fixed assets (¥0.004B for the Medical Equipment Sales Business and ¥0.0002B for the Nursing Care and Welfare Business).

Key Financial Indicators

【Profitability】The operating margin was 0.8%, a slight decline from approximately 0.9% in the prior year, while the net profit margin remained at 0.6%. The gross profit margin was low at 11.9%, reflecting the thin-margin structure characteristic of medical equipment distribution. ROE was 6.1%, below the generally accepted benchmark of 8% for capital efficiency. 【Cash Quality】Comprehensive income was ¥0.86B, below net income of ¥1.28B, with a negative ¥0.42B change in the valuation difference on other securities being the primary cause of the discrepancy. Special income included a ¥0.12B gain on the sale of investment securities, which should be distinguished from recurring earnings power. 【Investment Efficiency】The total asset turnover ratio was high, reflecting the characteristics of a wholesale distribution business, but conversion into returns on capital was limited due to low margins. 【Financial Soundness】The equity ratio was 16.7%, the current ratio was 108.9%, and the quick ratio was 93.0%; all were below generally accepted benchmarks, making the management of short-term funding requirements an ongoing area of focus.

Cash Flow Analysis

As the cash flow statement has not been disclosed, cash trends are analyzed based on changes in the balance sheet. Cash and deposits increased to ¥14.91B from ¥14.33B in the prior year, while total assets expanded by more than ¥12B to ¥125.16B from ¥113.02B. Increases in accounts receivable to ¥68.32B (¥57.99B in the prior year) and inventories to ¥14.87B (¥13.60B) were factors contributing to funding needs. On the liabilities side, accounts payable increased to ¥69.16B (¥60.11B), financing part of working capital, while short-term borrowings increased to ¥19.91B (¥16.76B). This suggests that the buildup of working capital associated with business expansion is being financed through short-term borrowings. Long-term borrowings declined to ¥3.81B from ¥4.47B in the prior year, indicating that the maturity profile of interest-bearing debt has shortened.

Earnings Quality

Operating income, which represents recurring earnings power, declined to ¥1.92B. However, profit before tax of ¥2.40B included special income of ¥0.12B, including a ¥0.12B gain on the sale of investment securities; excluding this temporary factor, recurring earning power was at a more challenging level. Non-operating income of ¥0.60B, including ¥0.01B in interest income and ¥0.03B in dividend income, exceeded non-operating expenses of ¥0.23B, including ¥0.17B in interest expense, thereby creating a structure in which ordinary income exceeded operating income. Income taxes were ¥1.11B, with the effective tax rate high at approximately 46.5%, placing pressure on final profit. Comprehensive income of ¥0.86B was below net income of ¥1.28B, and the negative ¥0.42B change in the valuation difference on other securities acted as an accrual-related source of fluctuation, a factor that should be noted when assessing earnings quality.

Earnings Forecast and Guidance

The full-year company forecasts are revenue of ¥305.00B (+5.6% YoY), operating income of ¥1.75B (-6.7%), and ordinary income of ¥2.30B (-5.1%). The Q3 year-to-date progress rates are 74.6% for revenue, 109.9% for operating income, 99.7% for ordinary income, and 98.6% for net income. Operating income has already exceeded the full-year forecast, implying that an operating loss of approximately ¥0.17B would need to be recorded in Q4 for results to land in line with the full-year forecast. This may be interpreted as incorporating deterioration in profitability toward Q4, seasonality, or conservative assumptions in the plan. No revisions have been made to either the earnings forecast or the dividend forecast for the current quarter.

Shareholder Returns

The Q2 dividend was ¥0 per share, while the full-year company forecast is an annual dividend of ¥20 per share. The payout ratio against forecast EPS of ¥58.46 is approximately 34.2%. This figure is a dividend-only payout ratio and is not a Total Return Ratio that takes share repurchases into account. The dividend burden itself is not excessive relative to the level of profit. However, because the company has a high degree of dependence on short-term borrowings and limited liquidity headroom, dividend sustainability will also be affected by the management of working capital and borrowings.

Risk Factors

1. Deteriorating profitability in the core business: The Medical Equipment Sales Business accounts for 94.1% of consolidated segment income, but while revenue increased +3.7%, segment income declined -9.1%, and the profit margin fell from 3.84% to 3.37%. Continued price competition or increases in procurement and logistics costs could have a significant impact on consolidated profit.

2. Financial leverage and short-term funding: The debt-to-equity ratio is approximately 4.99x, and short-term borrowings of ¥19.91B account for 83.9% of interest-bearing debt. Cash and deposits of ¥14.91B are equivalent to only 0.75x short-term borrowings. With a current ratio of 108.9% and a quick ratio of 93.0%, liquidity headroom against short-term obligations is limited.

3. Low-margin structure and tax burden: The gross profit margin is 11.9% and the operating margin is 0.8%, reflecting a thin-margin business in which even slight changes in selling prices or procurement costs can significantly affect profit. In addition, the effective tax rate is high at 46.5%, limiting the accumulation of final profit.

Industry Benchmark (For Reference; Company Research)

Profitability and Returns

Both the operating margin and net profit margin are significantly below the industry median, placing the company toward the lower end of the industry.

Growth and Capital Efficiency

The revenue growth rate is also slightly below the industry median, placing the company at or below the middle of the industry in terms of revenue growth.

※Source: Company research

Key Takeaways from the Earnings

1. Despite being in a phase of revenue growth, the profit margin of the core Medical Equipment Sales Business declined, meaning that revenue growth has not translated into profit growth. This is the structural feature of the current earnings results.

2. The full-year operating income forecast is set below the Q3 year-to-date actual result, making the trajectory of profitability in Q4 a key factor determining full-year performance.

3. The high effective tax rate of 46.5% and reliance on special income, including gains on the sale of investment securities, are factors that should be reviewed when assessing recurring levels of final profit.

Theoretical Share Price (Reference Value)

Sensitivity: ¥840–¥888 at cost of equity ±1%, and ¥861–¥865 at ω±0.1.

Notes:

• Because net income progress against the full-year forecast (99%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies whose progress is ahead of plan tend to exceed their forecasts. The adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson type; explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional where necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 earnings were operationally resilient at the consolidated margin level, but profit growth lagged revenue and balance-sheet leverage and refinancing exposure remain material constraints. Revenue rose 3.7% YoY to ¥227.68bn. Operating income declined 5.1% to ¥1.92bn, while ordinary income decreased 4.8% to ¥2.29bn. Net income attributable to owners fell 6.5% to ¥1.28bn, equivalent to EPS of ¥57.66. The gross margin was broadly unchanged at 11.9%, indicating that gross-profit generation kept pace with revenue growth. The operating margin was also effectively flat at 0.8%, with the modest decline in absolute operating income reflecting the very thin underlying margin structure. SG&A expenses increased 4.4% YoY, modestly faster than revenue, driven in part by salaries and allowances of ¥10.27bn. The medical equipment sales business remained the core business by segment profit contribution, generating ¥7.51bn of segment profit, but its profit fell 9.1% YoY despite 3.7% revenue growth. In contrast, the care and welfare business delivered 4.1% revenue growth and 14.1% segment-profit growth, lifting its segment margin. Corporate costs and goodwill amortization remained substantial deductions from segment profit, although the adjustment narrowed by ¥0.59bn YoY. Reported ROE of 8.2% is supported principally by financial leverage rather than strong margins, as the net margin was only 0.6%. The effective tax rate was elevated at 46.5%, reducing conversion of pre-tax profit into net income. Pre-tax income included a ¥1.16bn gain on sale of investment securities, which supported net income but is non-recurring. The balance sheet expanded primarily through trade receivables and trade payables, consistent with a working-capital-intensive distribution model. Management maintained full-year guidance, but Q3 cumulative operating income already exceeds the full-year forecast, implying a forecast Q4 operating loss if the outlook is retained. The full-year dividend forecast of ¥20 per share implies a moderate 34.2% dividend payout ratio based on forecast EPS. Near-term performance should be assessed through medical-equipment segment margin recovery, receivables collection, short-term debt refinancing, and the resolution of the unusually high tax burden.

Profitability Analysis

The reported annualized ROE of 8.2% decomposes into a 0.6% net profit margin, 2.425x asset turnover, and 5.99x financial leverage. This indicates that capital efficiency is derived mainly from rapid turnover of low-margin distribution revenue and a highly leveraged capital structure, rather than from pricing power or a high earnings margin. The most economically significant limiting factor is the 0.6% net margin: even a modest adverse movement in procurement conditions, reimbursement conditions, or operating costs can have a large effect on earnings. The gross margin was broadly stable at 11.9% YoY, while the operating margin remained approximately 0.8%, indicating limited operating leverage on the current revenue increase. SG&A grew 4.4% YoY versus revenue growth of 3.7%, creating modest cost pressure; salaries and allowances increased 4.3% to ¥10.27bn and rent rose 4.0% to ¥1.88bn. The medical equipment sales segment, the core business, recorded revenue of ¥222.91bn (+3.7% YoY) and segment profit of ¥7.51bn (-9.1%), with its segment margin declining to 3.4% from 3.8%. The care and welfare segment recorded revenue of ¥4.77bn (+4.1%) and segment profit of ¥0.47bn (+14.1%), improving its segment margin to 9.8% from 8.9%. Segment-level profitability therefore improved in care and welfare but deteriorated in the much larger medical equipment business. Unallocated corporate expenses and goodwill amortization reduced consolidated operating income by ¥6.05bn, although this was lower than the prior year's ¥6.64bn. The five-factor analysis shows a tax burden of 0.535, below the normal benchmark, reflecting the 46.5% effective tax rate. The interest burden exceeded 1.0 because pre-tax income benefited from non-operating and extraordinary gains; it should not be interpreted as evidence that interest costs are immaterial. Interest coverage of 11.35x remains adequate, but the low 0.8% EBIT margin leaves limited room for a sustained increase in borrowing costs. The quality alert for low operating efficiency is valid: an EBIT margin below 5% is structurally sensitive, although low margins are characteristic of healthcare equipment distribution and should be interpreted alongside high asset turnover.

Growth Assessment

Revenue growth of 3.7% was supported by both operating segments, with medical equipment sales contributing the overwhelming majority of consolidated revenue growth. The care and welfare business showed the stronger profit trajectory, with segment profit growth of 14.1%, but its smaller revenue base limits its ability to offset margin pressure in medical equipment distribution. Medical equipment segment profit declined despite higher sales, suggesting unfavorable product mix, procurement costs, pricing, or operating expenses within the core business. Consolidated gross profit increased 3.6% to ¥27.09bn, nearly matching sales growth, so the principal earnings pressure was not a major deterioration in gross margin. However, operating income fell because SG&A growth exceeded revenue growth. Full-year sales guidance is ¥305.00bn, and Q3 cumulative sales represent 74.6% of that target, broadly consistent with the standard 75% Q3 progress rate. Q3 cumulative ordinary income of ¥2.29bn represents 99.7% of the ¥2.30bn full-year forecast, materially ahead of the standard 75% pace. Q3 cumulative net income of ¥1.28bn represents 98.6% of the ¥1.30bn forecast, also well ahead of a normal seasonal run rate. Most notably, Q3 cumulative operating income of ¥1.92bn equals 109.9% of the full-year ¥1.75bn forecast. Retaining that forecast mathematically implies a Q4 operating loss of approximately ¥0.17bn, so the timing of seasonal costs, forecast conservatism, or a potential future revision is a key issue. The forecasted full-year operating-income decline of 6.7% YoY indicates that management does not yet expect revenue growth to translate into material profit expansion. The ¥1.16bn gain on sale of investment securities supported pre-tax income and is not a recurring driver of growth. The ¥0.04bn impairment charge was immaterial to group earnings and does not currently indicate a broad asset-quality problem.

Financial Health

Liquidity is positive but thin. The current ratio is 108.9%, above 1.0x, so current assets cover current liabilities; however, it remains below the 1.5x healthy benchmark. The quick ratio is 93.0%, below 1.0x, meaning that liquidity coverage excluding inventories is modest. Working capital was positive at ¥8.31bn, but the business carries substantial receivables of ¥68.32bn and inventories of ¥14.87bn. Current liabilities totaled ¥93.82bn, including ¥19.91bn of short-term loans and ¥69.16bn of trade payables. Short-term debt represents 83.9% of interest-bearing debt, creating a material refinancing-risk alert. Cash and deposits of ¥14.91bn cover only 0.75x short-term loans, so ongoing bank funding and working-capital turnover are important. Current assets of ¥102.13bn exceed current liabilities, mitigating an immediate maturity mismatch, but the cushion is relatively narrow for a distribution business reliant on timely receivable collection. The reported D/E ratio of 4.99x exceeds the 2.0x warning threshold and warrants explicit caution. This ratio is influenced by the company's large trade-payables base and low equity capitalization; interest-bearing debt alone is approximately 1.13x total equity. Debt/capital of 53.2% is elevated but remains below the 60% high-concern benchmark. Total assets increased by ¥12.14bn YoY, while total liabilities increased by ¥11.71bn and equity increased only ¥0.42bn, demonstrating that the balance-sheet expansion was predominantly liability financed. The capital adequacy ratio fell to 16.7% from 18.1%, reinforcing the need for disciplined leverage management. Goodwill was ¥0.97bn, equal to only 4.7% of equity and 0.8% of assets, so M&A-related asset concentration and goodwill impairment risk are currently limited. The quality alert on refinancing risk is material: short-dated borrowing is typical in a working-capital-intensive wholesaling model, but its scale makes access to committed bank facilities and stable credit terms central to the risk profile.

Notable B/S Changes

Accounts receivable: +¥10.03bn (+17.8%) YoY to ¥68.32bn - substantially faster growth than revenue; supports sales expansion but increases collection and liquidity sensitivity. Accounts payable: +¥9.05bn (+15.1%) YoY to ¥69.16bn - supplier financing expanded alongside receivables, reinforcing working-capital dependence. Total assets: +¥12.14bn (+10.7%) YoY to ¥125.16bn - balance-sheet growth was largely concentrated in operating working capital. Total liabilities: +¥11.71bn (+12.7%) YoY to ¥104.26bn - asset growth was predominantly liability funded, contributing to a lower capital adequacy ratio. Short-term loans: +¥3.15bn (+18.8%) YoY to ¥19.91bn - increased reliance on short-term funding heightens refinancing exposure. Inventories: +¥1.27bn (+9.3%) YoY to ¥14.87bn - inventory rose faster than sales, requiring monitoring of inventory turnover and product-demand alignment. Goodwill: -¥0.22bn (-18.8%) YoY to ¥0.97bn - amortization reduced goodwill exposure; the remaining balance is modest relative to equity and assets. Equity: +¥0.42bn (+2.1%) YoY to ¥20.90bn - equity growth materially lagged asset growth, while negative securities valuation movements reduced comprehensive income.

Cash Flow Quality

Dividend Sustainability

The full-year dividend forecast is ¥20 per share. Based on forecast EPS of ¥58.46, the implied dividend payout ratio is 34.2%, which is comfortably below the 60% sustainability benchmark. Based on Q3 cumulative EPS of ¥57.66, the planned dividend is also covered by reported earnings. The company reported no interim Q2 dividend, indicating that the indicated shareholder distribution is concentrated in the year-end payment. The moderate earnings payout provides some buffer against the group's thin operating margin and elevated leverage. Dividend sustainability nevertheless depends on maintaining banking liquidity and working-capital discipline because the balance sheet is heavily funded by payables and short-term loans. There is no announced dividend revision.

Risk Assessment

Business risks include Core medical equipment sales segment profitability weakened: segment profit fell 9.1% YoY to ¥7.51bn despite 3.7% revenue growth, demonstrating sensitivity to product mix, procurement costs, pricing, and operating expenses., The 11.9% gross margin and 0.8% EBIT margin leave limited protection against supplier price increases, competitive pricing, changes in hospital purchasing behavior, and reimbursement-related pressure in the healthcare distribution industry., Receivables were ¥68.32bn and the high receivable-days alert of 82 days indicates that collection timing is important to liquidity and may expose the company to hospital and healthcare-provider credit-cycle risk., The care and welfare business has improved margins but remains small relative to medical equipment sales, limiting diversification benefits at the consolidated level..

Financial risks include HIGH_LEVERAGE: the reported D/E ratio of 4.99x is above the 2.0x warning threshold. Large trade payables are a structural contributor, but the low equity base raises sensitivity to earnings volatility and funding conditions., REFINANCING_RISK: 83.9% of interest-bearing debt is short term, while cash covers only 0.75x of short-term loans. The company relies on continued refinancing capacity and stable banking relationships., HIGH_TAX_BURDEN: the 46.5% effective tax rate resulted in a tax burden of 0.535, reducing net-income conversion and contributing to the 6.5% decline in net income., CAPITAL_EFFICIENCY: annualized ROIC of 4.6% is below the 5% warning threshold, indicating returns may not sufficiently compensate for the capital and funding intensity of the business., Comprehensive income declined 36.1% YoY to ¥0.86bn, principally reflecting negative valuation differences on securities of ¥0.42bn..

Key concerns include The full-year operating-income forecast of ¥1.75bn is below the ¥1.92bn already recorded through Q3; the implied Q4 operating loss requires close scrutiny., HIGH_RECEIVABLE_DAYS: 82 days is above the 60-day alert threshold. Receivables increased ¥10.03bn YoY, or 17.8%, materially faster than revenue growth., LOW_GROSS_MARGIN and LOW_OPERATING_EFFICIENCY: 11.9% gross margin and 0.8% EBIT margin mean modest execution slippage can disproportionately affect profit., The non-recurring ¥1.16bn gain on sale of investment securities supported pre-tax earnings, reducing the comparability of net-income performance with recurring operating profit..

Investment Implications

Key takeaways include Revenue momentum remained positive, but the core medical equipment segment experienced profit compression., Reported annualized ROE of 8.2% is generated by high asset turnover and leverage rather than a strong net margin., Care and welfare delivered improved profitability, but its scale remains too small to offset core-segment margin pressure., The balance-sheet model is viable while receivables are collected efficiently and short-term borrowings are refinanced, but liquidity headroom is limited., Guidance arithmetic makes Q4 earnings seasonality and management's retained forecast a central monitoring issue..

Metrics to watch include Medical equipment sales segment margin and segment-profit trend, Receivable days, receivables growth, and trade-payables turnover, Short-term loan balance, cash-to-short-term-debt coverage, and refinancing terms, Consolidated gross margin, SG&A-to-sales ratio, and EBIT margin, Full-year operating-income guidance versus implied Q4 profitability, Effective tax rate and recurrence of investment-security disposal gains.

Regarding relative positioning, The company presents the profile of a high-turnover healthcare distributor: scale and working-capital circulation support returns, but margins are much lower than broad market profitability benchmarks. Its low goodwill exposure is a balance-sheet positive, while leverage, short-term debt reliance, receivables intensity, and sub-5% annualized ROIC are the principal offsets.